reports
LeonaBio Appoints Industry Veteran Mark F. Kubik as Chief Business Off...
LeonaBio Appoints Industry Veteran Mark F. Kubik as Chief Business Officer Brings more than 25 years of biopharma business development and corporate strategy expertise BOTHELL, Wash., Feb. 03, 2026 (GLOBE NEWSWIRE) -- LeonaBio, Inc. (NASDAQ: LONA), a clinical-stage biopharmaceutical company dedicated to the development of novel therapeutics for diseases with high unmet medical needs, today announced the appointment of Mark F. Kubik as Chief Business Officer. In this role, Mr. Kubik will lead LeonaBio’s business development strategy and execution, with responsibility for licensing, partn...
INmune Bio Inc Issues Shareholder Letter Reviewing 2025 Milestones and...
INmune Bio Inc Issues Shareholder Letter Reviewing 2025 Milestones and Outlining 2026 Strategic Initiatives Boca Raton, FL, Jan. 27, 2026 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ: INMB), a clinical-stage inflammation and immunology company, presents the following letter to investors from David Moss, CEO: Dear Fellow Shareholders, As we reflect on 2025, I want to thank you for your continued support of INmune Bio. This past year marked an important period of execution, discipline, and focus as we advanced our mission to develop innovative therapies that address serious neuroinflamma...
Cassava Announces Publication of Peer-Reviewed Phase 3 Results for Sim...
Cassava Announces Publication of Peer-Reviewed Phase 3 Results for Simufilam in Alzheimer’s Disease in the Journal of Prevention of Alzheimer’s Disease As previously disclosed, the studies did not meet pre-specified co-primary, secondary, or exploratory biomarker endpoints The paper provides a detailed analysis of the RETHINK-ALZ and REFOCUS-ALZ studies and confirms simufilam’s favorable safety profile in these studies Exploratory post-hoc analyses offer informative insights AUSTIN, Texas, Jan. 13, 2026 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (NASDAQ: SAVA, “Cassava”, the “Company...
Athira Pharma Announces Name Change to LeonaBio, Inc. with New Ticker ...
Athira Pharma Announces Name Change to LeonaBio, Inc. with New Ticker “LONA” New name to reflect recent transformative acquisition of rights to Phase 3 program in metastatic breast cancer and commitment to continued leadership, resilience and innovation BOTHELL, Wash., Jan. 09, 2026 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a clinical-stage biopharmaceutical company dedicated to the development of novel therapeutics for diseases with high unmet medical needs, today announced that it has changed its name to LeonaBio, Inc. The name change aligns with the Company’s transforma...
BioVie Completes Enrollment in Phase 2 SUNRISE-PD Trial in Early Parki...
BioVie Completes Enrollment in Phase 2 SUNRISE-PD Trial in Early Parkinson’s Disease - Patient-centric trial aiming to evaluate whether bezisterim can help delay disease progression reaches enrollment milestone - - Topline Results from the SUNRISE-PD Trial Expected in 1H 2026 - CARSON CITY, Nev., Jan. 08, 2026 (GLOBE NEWSWIRE) -- BioVie Inc. (NASDAQ: BIVI) (“BioVie” or the “Company”), a clinical-stage company developing innovative drug therapies for neurological and neurodegenerative diseases, today announced that it has completed enrollment of 60 patients in its Phase 2 SUNRISE-PD clin...
Cassava Announces Agreement to Settle Securities Class Action Litigati...
Cassava Announces Agreement to Settle Securities Class Action Litigation AUSTIN, Texas, Dec. 23, 2025 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (NASDAQ: SAVA, “Cassava”, the “Company”), a biotechnology company focused on developing novel, investigational treatments for central nervous system (CNS) disorders such as Tuberous Sclerosis Complex (TSC)-related epilepsy, today announced that it has reached a definitive agreement to resolve the previously disclosed consolidated securities class action litigation pending in the United States District Court for the Western District of Texas Austi...
Athira Pharma Announces Exclusive License to Lasofoxifene Phase 3 Deve...
Athira Pharma Announces Exclusive License to Lasofoxifene Phase 3 Development Program for Metastatic Breast Cancer Candidate and a Financing for up to $236 Million Phase 3 Development Program of Novel Selective Estrogen Receptor Modulator (SERM) Represents Potential Multi-Billion Dollar Opportunity as Treatment Option for Patients with ESR1-Mutations Financing Co-Led by Commodore Capital, Perceptive Advisors and TCGX Supports Development of Lasofoxifene through Phase 3 Clinical Topline Data Readout and Regulatory Milestones Conference Call Today at 8:30 am Eastern Time BOTHELL, Wash., De...
Peer Reviewed Study Highlights Therapeutic Potential Around Applicatio...
Peer Reviewed Study Highlights Therapeutic Potential Around Application of Stromal Cell Therapies Such as INmune Bio’s CORDStrom™ Platform Boca Raton, FL, Dec. 05, 2025 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ: INMB) (“INmune” or the “Company”), a clinical-stage inflammation and immunology company, announces a recently published overview of future applications and research areas for mesenchymal stromal cell (MSC) therapies, such as INmune’s CORDStrom™ platform. The article, titled, “Fate and Function of Exogenously Administered MSCs: Current Insights and Future Directions,” was publi...
INmune Bio Reports New Phase 2 Grey Matter Imaging Data at CTAD Confer...
INmune Bio Reports New Phase 2 Grey Matter Imaging Data at CTAD Conference Reinforcing XPro1595’s Evidence Base in High-Inflammation Alzheimer's Patients Boca Raton, FL, Dec. 01, 2025 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ: INMB), a clinical-stage biotechnology company developing inflammation and immunology therapies targeting innate immune dysfunction, announces new neuroimaging data from its Phase 2 MINDFuL trial of XPro1595 in patients with early Alzheimer’s disease (AD) and elevated neuroinflammation. The results will be presented at the 18th Clinical Trials on Alzheimer’s Dise...
Join Biovie’s Exclusive Live Investor Webinar and Q&A Session on Decem...
Join Biovie’s Exclusive Live Investor Webinar and Q&A Session on December 9 CARSON CITY, Nev., Nov. 19, 2025 (GLOBE NEWSWIRE) -- BioVie Inc. (NASDAQ: BIVI) (“BioVie” or the “Company”), a clinical-stage company developing innovative drug therapies for neurological and neurodegenerative diseases, is pleased to invite investors to a webinar on December 9, 2025, at 4:15 p.m. ET. The exclusive event, hosted by RedChip Companies, will feature Cuong Do, President and CEO of BioVie, who will discuss bezisterim (NE3107), BioVie’s first-in-class, orally available small molecule that targets inflam...
INmune Bio Announces Two Presentations at the Upcoming 18th Annual CTA...
INmune Bio Announces Two Presentations at the Upcoming 18th Annual CTAD Conference Boca Raton, FL, Nov. 18, 2025 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ: INMB), a clinical-stage inflammation and immunology company, today announces two presentations at the upcoming 18th Clinical Trials on Alzheimer’s Disease conference (CTAD), in San Diego, CA on December 1-4, 2025. Presentations: Title:XPro1595, a Selective Soluble TNF Neutralizer, in Early Alzheimer’s Disease with Inflammation (ADi): Results from the Phase 2 MINDFuL Trial Date:Monday, December 1, until Tuesday December 2, 2025 T...
Cassava Reports Q3 2025 Financials Results and Provides Business Updat...
Cassava Reports Q3 2025 Financials Results and Provides Business Update Simufilam advancing towards a clinical study expected to begin in H1 2026 for the potential treatment of TSC-related epilepsyFurther fortified our strategic capabilities with the appointment of Dawn C. Bir to the Board of Directors$106.1 million in cash and cash equivalents at September 30, 2025. Expected to support operations into 2027 AUSTIN, Texas, Nov. 12, 2025 (GLOBE NEWSWIRE) -- – Cassava Sciences, Inc. (NASDAQ: SAVA, “Cassava”, the “Company”), a biotechnology company focused on developing novel, investigation...
Athira Pharma Reports Third Quarter 2025 Financial Results and Provide...
Athira Pharma Reports Third Quarter 2025 Financial Results and Provides Business Update Continuing to explore strategic alternatives focusing on maximizing stockholder value Presented results from Phase 1 clinical trial of ATH-1105 in healthy volunteers demonstrating a favorable safety and tolerability profile as well as dose proportional pharmacokinetics and CNS penetration, supporting continued clinical development BOTHELL, Wash., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a clinical stage biopharmaceutical company focused on developing small molecules to...
INmune Bio Inc. Announces Third Quarter 2025 Results and Provides Busi...
INmune Bio Inc. Announces Third Quarter 2025 Results and Provides Business Update Company to Host Conference Call Today, October 30, at 4:30pm ET BOCA RATON, Fla., Oct. 30, 2025 (GLOBE NEWSWIRE) -- (NASDAQ: INMB) (the “Company”), a clinical-stage inflammation and immunology company focused on developing treatments that harness the patient’s innate immune system to fight disease, today announces its financial results for the quarter ended September 30, 2025 and provides a business update. Q3 2025 and Recent Corporate Highlights CORDStrom™ Platform: Announced successful completion o...
INmune Bio Inc. to Report Third Quarter 2025 Financial Results and Pro...
INmune Bio Inc. to Report Third Quarter 2025 Financial Results and Provide a Corporate Update on Thursday, October 30, 2025 Management to host conference call and webcast at 4:30 pm ET on that day Boca Raton, Florida, Oct. 23, 2025 (GLOBE NEWSWIRE) -- INmune Bio Inc. (NASDAQ: INMB) (the “Company”), INmune Bio Inc. (NASDAQ: INMB), a clinical-stage inflammation and immunology company, today announces that it will host a conference call on Thursday, October 30, 2025 at 4:30 PM Eastern Time to discuss results for its third quarter ended September 30, 2025 and to provide a corporate update. ...
Cassava Sciences Appoints Dawn C. Bir to the Board of Directors
Cassava Sciences Appoints Dawn C. Bir to the Board of Directors AUSTIN, Texas, Oct. 22, 2025 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (NASDAQ: SAVA, “Cassava”, the “Company”), a biotechnology company focused on developing novel, investigational treatments for central nervous system (CNS) disorders such as Tuberous Sclerosis Complex (TSC)-related epilepsy, today announced the appointment of Ms. Dawn C. Bir to its Board of Directors (the Board). Dawn Bir is a seasoned biopharmaceutical executive and board member with a track record of contributing to the successful development and value ...
- Jonathan Moreland
VIRC VIRCO MANUFACTURING CORP.
THFF FIRST FINANCIAL CORP. (INDIANA)
SSNC SS&C TECHNOLOGIES HOLDINGS INC.
SPWH SPORTMANS WAREHOUSE HOLDINGS
PSEC PROSPECT CAPITAL CORPORATION
FDS FACTSET RESEARCH SYSTEMS INC.
CAPL CROSSAMERICA PARTNERS LP
CALM CAL-MAINE FOODS INC.
CAG CONAGRA BRANDS INC.
ANGO ANGIODYNAMICS INC.
ASA ASA
ADC AGREE REALTY CORPORATION
RIGN TRANSOCEAN LTD.
RVP RETRACTABLE TECHNOLOGIES INC.
TRT TRIO TECH INTERNATIONAL
FSFG FIRST SAVINGS FINANCIAL GROUP INC.
KYN KAYNE ANDERSON MLP INVESTMENT CO.
AMBC AMBAC FINANCIAL GROUP INC.
GWRS GLOBAL WATER RESOURCES
BRT BRT APARTMENTS
ZIVO ZIVO BIOSCIENCE
CPSH INC.
FUND CPS TECHNOLOGIES
FGBI ROYCE FOCUS TRUST
STRO INC.
SAVA FIRST GUARANTY BANCSHARES
DX SUTRO BIOPHARMA
PNTG CASSAVA SCIENCES
PCB DYNEX CAPITAL INC.
WWR PENNANT GROUP
ACET PACIFIC CITY FINANCIAL CORP
ALTM WESTWATER RESOURCES
CGEM ADICET BIO INC
OPEN ALTUS MIDSTREAM COMPANY (A)
GGZ CULLINAN ONCOLOGY INC
IMRX OPENDOOR TECHNOLOGIES INC.
REFI GABELLI GLOBAL SMALL AND MID CAP VALUE TRUST
PEPG IMMUNEERING CORP
VANI CHICAGO ATLANTIC REAL ESTATE FINANCE INC
UAMY PEPGEN INC
SOC VIVANI MEDICAL INC
LAW U S ANTIMONY CORP
MRAI SABLE OFFSHORE CORP
HYMC CS DISCO INC
SABS MARPAI
INC.
HYCROFT MINING HOLDING CORPORATION
BIG CYPRESS ACQUISITION CORP.
INmune Bio to Participate in Dermatologic Rare Disease Panel at the Ma...
INmune Bio to Participate in Dermatologic Rare Disease Panel at the Maxim Growth Summit 2025 Boca Raton, FL, Oct. 14, 2025 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ: INMB), a clinical-stage inflammation and immunology company, today announces that David Moss, Chief Executive Officer will participate in a Dermatologic Rare Disease Panel at the Maxim Growth Summit presented by Maxim Group LLC. The Summit is being held on October 22 – 23, 2025 at the Hard Rock Hotel in New York City. The panel will be moderated by Jason McCarthy, Ph.D., Senior Managing Director, Head of Biotechnology Re...
- Jonathan Moreland
WOR WORTHINGTON INDUSTRIES INC.
SPWH SPORTMANS WAREHOUSE HOLDINGS
PSEC PROSPECT CAPITAL CORPORATION
FDS FACTSET RESEARCH SYSTEMS INC.
CALM CAL-MAINE FOODS INC.
CAG CONAGRA BRANDS INC.
ANGO ANGIODYNAMICS INC.
KRNY KEARNY FINANCIAL CORP.
ADC AGREE REALTY CORPORATION
CULP CULP INC.
RIGN TRANSOCEAN LTD.
RVP RETRACTABLE TECHNOLOGIES INC.
FSFG FIRST SAVINGS FINANCIAL GROUP INC.
KYN KAYNE ANDERSON MLP INVESTMENT CO.
AMBC AMBAC FINANCIAL GROUP INC.
HAIN THE HAIN CELESTIAL GROUP
GWRS INC.
AROC GLOBAL WATER RESOURCES
ZIVO ARCHROCK INC.
CPSH ZIVO BIOSCIENCE
FUND INC.
ARVN CPS TECHNOLOGIES
FGBI ROYCE FOCUS TRUST
BCDA INC.
SAVA ARVINAS HOLDING
DX FIRST GUARANTY BANCSHARES
AOUT BIOCARDIA
ACET CASSAVA SCIENCES
ALTM DYNEX CAPITAL INC.
CGEM AMERICAN OUTDOOR BRANDS
OPEN INC.
GGZ ADICET BIO INC
IMRX ALTUS MIDSTREAM COMPANY (A)
ABSI CULLINAN ONCOLOGY INC
PEPG OPENDOOR TECHNOLOGIES INC.
MRVL GABELLI GLOBAL SMALL AND MID CAP VALUE TRUST
UAMY IMMUNEERING CORP
PRAX ABSCI CORP
LAW PEPGEN INC
MRAI MARVEL BIOSCIENCES CORP
JSPR U S ANTIMONY CORP
BDSX PRAXIS PRECISION MEDICINES INC
SABS CS DISCO INC
MARPAI
INC.
AMPLITUDE HEALTHCARE ACQUISITION CORP
BIODESIX INC
BIG CYPRESS ACQUISITION CORP.
- Jonathan Moreland
WOR WORTHINGTON INDUSTRIES INC.
SPWH SPORTMANS WAREHOUSE HOLDINGS
PSEC PROSPECT CAPITAL CORPORATION
NMFC NEW MOUNTAIN FINANCE CORPORATION
NGL NGL ENERGY PARTNERS LP
KRNY KEARNY FINANCIAL CORP.
ADC AGREE REALTY CORPORATION
CULP CULP INC.
RIGN TRANSOCEAN LTD.
FSFG FIRST SAVINGS FINANCIAL GROUP INC.
AMBC AMBAC FINANCIAL GROUP INC.
HAIN THE HAIN CELESTIAL GROUP
SMRT INC.
MBIN SMARTSPACE SOFTWARE
AROC MERCHANTS BANCORP
FUND ARCHROCK INC.
ARVN ROYCE FOCUS TRUST
FGBI INC.
BCDA ARVINAS HOLDING
UUU FIRST GUARANTY BANCSHARES
SAVA BIOCARDIA
DX UNIVERSAL SECURITY INSTRUMENTS INC.
AOUT CASSAVA SCIENCES
ALXO DYNEX CAPITAL INC.
ALTM AMERICAN OUTDOOR BRANDS
AMR INC.
OPEN ALX ONCOLOGY HOLDINGS
GGZ ALTUS MIDSTREAM COMPANY (A)
IMRX ALPHA METALLURGICAL RESOURCES INC
ABSI OPENDOOR TECHNOLOGIES INC.
RYAN GABELLI GLOBAL SMALL AND MID CAP VALUE TRUST
PEPG IMMUNEERING CORP
MRVL ABSCI CORP
BUKS RYAN SPECIALTY GROUP HLDGS INC
OBLG PEPGEN INC
VANI MARVEL BIOSCIENCES CORP
UAMY BUTLER NATIONAL CORP
PRAX OBLONG INC
NCDL VIVANI MEDICAL INC
NEXT U S ANTIMONY CORP
MRAI PRAXIS PRECISION MEDICINES INC
JSPR NUVEEN CHURCHILL DIRECT LENDING CORP
BDSX NEXTSOURCE MATERIALS INC.
SABS MARPAI
INC.
AMPLITUDE HEALTHCARE ACQUISITION CORP
BIODESIX INC
BIG CYPRESS ACQUISITION CORP.
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.